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Despite several new therapeutic options, multiple myeloma (MM) patients experience
multiple relapses and inevitably become refractory to treatment. Insights into drug
resistance mechanisms may lead to the development of novel treatment strategies.
The S100 family is comprised of 21 calcium binding protein members with 17 S100
genes located in the 1q21 region, which is commonly amplified in MM. Dysregulated
expression of S100 family members is associated with tumor initiation, progression and
inflammation. However, the relationship between the S100 family and MM pathogenesis
and drug response is unknown. In this study, the roles of S100 members were
systematically studied at the copy number, transcriptional and protein level with patients’
survival and drug response. Copy number analysis revealed a predominant pattern
of gains occurring in S100 genes clustering in the 1q21 locus. In general, gains of
genes encoding S100 family members associated with worse patient survival. However,
S100 gene copy number and S100 gene expression did not necessarily correlate,
and high expression of S100A4 associated with poor patient survival. Furthermore,
integrated analysis of S100 gene expression and ex vivo drug sensitivity data showed
significant negative correlation between expression of S100 family members (S100A8,
S100A9, and S100A12) and sensitivity to some drugs used in current MM treatment,
including proteasome inhibitors (bortezomib, carfilzomib, and ixazomib) and histone
deacetylase inhibitor panobinostat. Combined proteomic and pharmacological data
exhibited significant negative association of S100 members (S100A4, S100A8, and
S100A9) with proteasome inhibitors and panobinostat. Clinically, the higher expression
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of S100A4 and S100A10 were significantly linked to shorter progression free survival
in patients receiving carfilzomib-based therapy. The results indicate an association and
highlight the potential functional importance of S100 members on chromosome 1q21
in the development of MM and resistance to established myeloma drugs, including
proteasome inhibitors.
Keywords: multiple myeloma, S100 protein family, drug resistance, proteasome inhibitors, panobinostat
INTRODUCTION
Multiple myeloma (MM) is the second most common
hematologic malignancy characterized by the expansion of
clonal plasma cells. The advent of novel agents, such as
immunomodulatory drugs (IMiDs) and proteasome inhibitors
(PIs), have markedly improved patient outcome (Fonseca et al.,
2017). Although the majority of patients initially respond to
therapy, eventually patients experience multiple relapses, and
ultimately become refractory to treatment (Rajkumar, 2011). It
is therefore important to identify factors predicting response to
treatment, decipher drug resistance mechanisms, and guide the
development of future treatment approaches.
Previous studies have demonstrated cytogenetic abnormalities
can be used to determine MM patient prognosis (Palumbo et al.,
2015; Manier et al., 2017). The gain/amplification of chromosome
1q21 (1q21+) is among the most frequent chromosomal
aberrations in MM, occurring in approximately 40% of patients
with greater prevalence in relapsed patients than those with
newly diagnosed disease (Marzin et al., 2006). Several studies
have shown that 1q21+ associates with poor overall survival
in MM patients, independent of other high-risk chromosomal
abnormalities (Hanamura et al., 2006; Giri et al., 2020). In
addition, 1q21+ confers inferior outcome in patients treated with
IMiDs and PIs (Shaughnessy, 2005; Nahi et al., 2016; Schmidt
et al., 2019). Investigations of the genes within the 1q21 region
have provided some insight into the mechanisms that could
contribute to the poor outcome of patients with this aberration.
These include CKS1B (Shaughnessy, 2005), MCL1 (Samo et al.,
2018), IL6R (Teoh et al., 2020), and ADAR (Teoh et al., 2020),
all of which have been shown to promote MM progression.
Inhibitors of the Mcl-1 protein have shown potent anti-myeloma
activity in 1q21-amplified MM patients (Slomp et al., 2019).
However, the influence of other 1q21 genes on MM pathogenesis
and patient response to treatment is largely unknown.
The S100 protein family is the largest subgroup of calcium
binding EF-hand type proteins and consists of at least 21
members that tend to form homodimeric and/or heterodimeric
complexes with each other (Heizmann et al., 2002). The majority
(S100A1-S100A16, TCHLL1) are in the 1q21 region, while S100B,
S100G, S100P, and S100Z are located at 21q22, Xp22, 4p16, and
5q14, respectively. All S100 members except for S100G are Ca2+
sensor proteins and participate in multiple biological processes,
including cell proliferation, growth, motility, apoptosis,
differentiation, inflammatory response, Ca2+ homeostasis,
protein synthesis, transcription, and membrane permeability
(Donato et al., 2013; Kuberappa et al., 2016). However, S100
proteins showed cell-specific expression patterns and non-
redundant functions by interacting with a unique set of target
proteins (Donato, 2001). Certain S100 proteins have intercellular
and/or extracellular functions. Within cells, S100 proteins
interact with multiple target proteins and exert a broad range
of cellular functions, including cell proliferation, differentiation,
calcium homeostasis and energy metabolism. Extracellular
S100 proteins induce proinflammatory responses and immune
escape by activating JAK-STAT, NF-κB, and MAPK pathways
by binding to toll-like receptor 4 (TLR4), receptor for advanced
glycation end products (RAGE), and other cell surface receptors
(Donato et al., 2013). Dysregulated expression of many S100
family members have been described in various types of cancers
and implicated in tumor cell proliferation, invasion, metastasis,
angiogenesis, and immune evasion (Bresnick et al., 2015).
S100A4 has been shown to promote acute myeloid leukemia
(AML) survival (Alanazi et al., 2020) and S100A8 is considered as
a prognostic marker for AML (Nicolas et al., 2011). Upregulation
of S100A6 correlates with poor outcome of pancreatic cancer
patients (Vimalachandran et al., 2005). Overexpression of
S100A8 and S100A9 associates with the progression of many
solid tumors, including prostate (Grebhardt et al., 2014),
colorectal (Ichikawa et al., 2011), and breast cancer (Goh et al.,
2017). S100A13 has been shown to promote melanoma metastasis
and chemoresistance (Azimi et al., 2014). Furthermore, several
studies have reported some S100 members participated in
drug resistance: higher expression of S100A8 and S100A9 leads
to glucocorticoid resistance in MLL rearranged infant acute
lymphoid leukemia (Spijkers-Hagelstein et al., 2012), while
our previous study revealed elevated expression of S100A8 and
S100A9 negatively associate with sensitivity to the BCL2 inhibitor
venetoclax in AML (Karjalainen et al., 2019). Some S100 proteins
(S100A3, S100A9, S100A12, and S100A13) were upregulated
in normal plasma cells compared with MM cells (Zhan et al.,
2002; Amit et al., 2021). In a recent study, S100A4, S100A10,
and S100A11 showed significant upregulation in MM non-
responding versus responding patients treated with a combined
regimen, including daratumumab, carfilzomib, lenalidomide,
and dexamethasone (KARA-KRD), and their overexpression
were also involved in clonal evolution of a primary refractory
MM patient responding to KARA-KRD treatment (Cohen et al.,
2021). Although S100 proteins are known to contribute to cancer
progression and drug resistance, their functions in MM and
possible effects on treatment response remain unclear.
The aims of this study are to investigate the roles of S100
in MM progression using cytogenetic profiling, copy number
analysis, gene expression, protein expression, and clinical
outcome data. Furthermore, by integrating gene expression,
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ex vivo drug response, and clinical response data, we aimed
to determine whether S100 expression could guide treatment




Bone marrow (BM) aspirates and skin biopsies were obtained
from 56 newly diagnosed and 115 relapsed/refractory patients
after informed consent using protocols in accordance with
the Declaration of Helsinki and approved by an ethical
committee of the Helsinki University Hospital (study numbers
239/13/03/00/2010 and 303/13/03/01/2011). Mononuclear
cells were isolated by Ficoll-Paque gradient centrifugation (GE
Healthcare, Little Chalfont, Buckinghamshire, United Kingdom),
followed by enrichment of CD138+ plasma cells using the
EasySepTM Human CD138 Positive Selection Kit (StemCell
Technologies, Vancouver, BC, Canada). Cytogenetic data
were generated using routine diagnostic fluorescence in situ
hybridization technology following the European Myeloma
Network 2012 guidelines (Caers et al., 2018). Fluorescence
in situ hybridization (FISH) was performed at patient diagnosis
using the following probes: Vysis IGH/FGFR3 (4p16/14q32,
DC.DF), Vysis IGH/CCND1 (11q13/14q32, DC.DF), Vysis
TP53 (17p13.1), Vysis 1q21 CKS1B/1p32 CDKN2C, and
Vysis D13S319/13q34. Patient characteristics are described in
Supplementary Table 1.
RNA Sequencing and Analysis
RNA sequencing was performed for 116 MM patient samples
as described previously (Kumar et al., 2017). Briefly, RNA
was prepared from freshly isolated CD138+ cells with the
Qiagen AllPrep kit (Qiagen, Hilden, Germany) and ribosomal
RNA was depleted using the Ribo-ZeroTM rRNA Removal Kit
(Epicenter, Madison, WI, United States), then reverse transcribed
to double stranded cDNA (SuperScriptTM Double Stranded
cDNA Synthesis Kit, Thermo Fisher Scientific, Carlsbad, CA,
United States). Illumina-compatible RNA sequencing libraries
were prepared using ScriptSeqTM technology and sequenced
on IlluminaHiSeq R© 1500 or 2500 instruments (Illumina, San
Diego, CA, United States). After pre-processing, filtered reads
were aligned to the GRCh38 human reference genome using the
STAR aligner tool (Dobin et al., 2013). Gene read counts were
normalized using the reads per kilobase of transcript per million
mapped reads (RPKM) method. A cutoff value >1 RPKM was
used to filter the expressed S100 genes. Data are available on the
Center for Open Science platform OSF1.
Exome Sequencing and Copy Number
Analysis
Genomic DNA was isolated from CD138+ cells and skin
biopsies (n = 168) with the DNeasy Blood & Tissue kit or
AllPrep R© DNA/RNA/miRNA Universal kit (Qiagen). Exome
1https://osf.io
capture was performed with The SeqCap R© EZ MedExome kit
(Roche NimbleGen, Madison, WI, United States), SureSelect
Clinical Research Exome kit, or SureSelect Human All Exon V5
kit (Agilent Technologies, Santa Clara, CA, United States) and
exomes sequenced on a HiSeq R© 1500 or 2500 instrument. Gene
copy numbers were estimated from exome sequencing data as
previously described (Sulonen et al., 2011; Kumar et al., 2021).
Copy number variants (CNVs) were identified using the CopyCat
tool2. Patient with log2 copy number ratio≥ 0.5 were considered
as a gain while ratio <−0.6 were considered as deletion. Data are
available in the OSF platform (see text footnote 1).
Proteome Analysis
Proteome analysis was performed for 35 MM patient samples as
described previously (Tierney et al., 2021). Briefly, CD138+ cells
were lysed in RIPA buffer (Cell Signaling Technology, Danvers,
MA, United States). The whole cell lysates were then digested
and loaded onto a Q Exactive (Thermo Fisher Scientific,
Hemel Hempstead, United Kingdom) high-resolution accurate
mass spectrometer connected to a Dionex Ultimate 3000
(RSLCnano) chromatography system (Thermo Fisher Scientific,
Hemel Hempstead, United Kingdom). Protein identification and
quantification was performed using MaxQuant v1.5.2.83. Perseus
v.1.5.6.04 was used for data analysis, processing, and visualization.
Normalized label-free quantification intensity values were used
as the quantitative measurement of protein abundance for
subsequent analysis. The dataset is available on the OSF platform
(see text footnote 1).
Drug Sensitivity and Resistance Testing
(DSRT) of MM Patient Cells
The sensitivity of CD138+ cells from the MM patient samples
(n = 142) was assessed to up to 308 small molecule drugs
including approved and investigational compounds as described
previously (Majumder et al., 2017). The drugs were pre-plated
onto 384-well plates in five concentrations in a 10,000-fold
concentration range. The cells were suspended in RPMI 1640
medium supplemented with 10% fetal bovine serum, 2 mM
L-glutamine, penicillin (100 U/ml), streptomycin (100 µg/ml),
and 25% conditioned medium from the HS-5 human BM stromal
cell line with 5000 cells added per well. After 72 h incubation at
37◦C and 5% CO2, cell viability was measured using the CellTiter-
Glo (CTG) assay (Promega, Madison, WI, United States) with
a PHERAstar FS plate reader (BMG LABTECH, Ortenberg,
Germany). A drug sensitivity score (DSS) was calculated based on
a modified area under the dose-response curve calculation (Yadav
et al., 2014). Selective drug sensitivity scores (sDSS) for the MM
patient samples were calculated by subtracting the median DSS of
BM mononuclear cells from eight healthy donors.
Drug Testing for MM Cell Lines
KMS-12-BM, NCI-H929, U-266, SK-MM-1, OPM-2, and MM.1S
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Collection (ATCC, Wesel, Germany). All cell lines were cultured
in RPMI-1640 medium, supplemented with 10–20% heat-
inactivated fetal bovine serum (FBS), 2 mM L-glutamine,
100 U/mL penicillin, and 100 µg/ml streptomycin (Gibco,
Thermo Fisher Scientific, Waltham, MA, United States) at
37◦C in a humidified incubator with 5% CO2. The compounds
were pre-plated onto 384-well plates in five concentrations in
a 10,000-fold concentration range. The cells were seeded in
25 µl volume of medium at the density of 5000 cells/well. After
72 h, cell viability was measured using the CTG assay. The
data were normalized to negative control (dimethyl sulfoxide
vehicle only) and the positive controls wells (100 µmol/l
benzethonium chloride).
Data Validation
To validate our results, clinical, gene expression and genomic
variant data (CNV) were obtained from the Multiple Myeloma
Research Foundation (MMRF) Relating Clinical Outcomes in
MM to Personal Assessment of Genetic Profile (CoMMpass)
study (IA15a release)5,6. Specifically, the normalized gene
expression table of Cufflinks gene FPKM and Exome per gene
largest segment were used for gene expression and CNV analysis.
Gene expression and CNV datasets include 892 and 1044 patient
cases, respectively. A total of 54 paired MM samples were used
to compare S100 gene expression between the diagnostic and the
first relapse samples.
Statistical Analysis
Statistical analyses were performed with R version 4.0.3 (2020-
10-10) and Prism 9 (GraphPad, La Jolla, CA, United States).
Drug response comparisons were computed with the Mann–
Whitney U test and correlation analyses with the Spearman’s
rank correlation coefficient test. Gene expression values were
compared using the unpaired two-sample t-test. Baseline
characteristics between patients with and without 1q21 gain
or S100 gain were analyzed by the chi-square test and the
Fisher’s exact test. Overall survival (OS) and progression-
free survival (PFS) were calculated using the Kaplan-Meier
method, and differences among survival curves were analyzed
using a log-rank test. Cox proportional hazards regression
analysis was used to examine the association of S100 expression
with OS, adjusting for potential confounders including age,
gender, and cytogenetic alterations. All statistical tests applied
in this study were two-tailed and P-values below 0.05 were
considered significant.
RESULTS
Prevalence and Prognostic Significance
of S100 Copy Number Change
Cytogenetic data (Supplementary Table 1) showed 1q21 gain in
48.21% of samples (81/168), del(13q) 55.36% (93/168), del(17p)
19.64% (33/168), t(4:14) 19.04% (32/168), and t(11:14) 19.04%
5https://research.themmrf.org
6www.themmrf.org
(32/168). Seventeen S100 genes (S100A1, S100A2, S100A3,
S100A4, S100A5, S100A6, S100A7, S100A7A, S100A8, S100A9,
S100A10, S100A11, S100A12, S100A13, S100A14, S100A16, and
TCHLL1), located as a cluster on chromosome 1q21, exhibited
copy number gains in 24.4% (41/168) of the MM samples
(Figure 1A and Supplementary Table 2). Of the 168 MM
patient samples analyzed, there were 4 newly diagnosed MM
patients (NDMM) with S100 gain and 1q21 gain, no NDMM
samples with S100 gain and no 1q21 gain, 10 NDMM samples
with 1q21 gain and no S100 gain, 31 relapsed/refractory MM
(RRMM) patients with S100 gain and 1q21 gain, 6 RRMM with
S100 gain and no 1q21 gain, and 33 RRMM with 1q21 gain
and no S100 gain (Figure 1B and Supplementary Table 2).
Correlation analysis of S100 gain with disease stage and 1q21
gain showed S100 gains were detected more frequently in RRMM
samples than samples from NDMM samples and co-occurred
with 1q21 gain, indicating 1q21 gain is a major factor for S100
gain (Table 1). Copy number gains of S100A9, S100A7, S100A7A,
and S100A8 significantly correlated with poor overall survival in
MM patients from our internal (FIMM) dataset (Supplementary
Table 3). Overall, S100 genes in the 1q21 region show similar
gains and have a negative impact on survival (Figure 1C).
Since patients with S100 gain were more likely to have 1q21
gain, a 4-level measure was created for survival analysis. The
median overall survival (OS) for each of the four categories was
120 months for no documented 1q21 or S100 gain, 76 months
for 1q21 gain but no S100 gain, 46 months for S100 gain
but no 1q21 gain, and 76 months for both S100 gain and
1q21 gain. Patients with 1q21 gain and without S100 gain and
patients with S100 gain and without 1q21 gain were associated
with significantly poorer outcome of in our FIMM dataset
(Figure 1D). The CoMMpass dataset was used for validation
and confirmed the high frequencies of S100 gene gains in 1044
samples (Supplementary Figures 1A,B). Integrated analysis of
copy number variation (CNV) and gene expression showed that
only S100A13 had a significant positive correlation (r = 0.42)
between copy number gains and gene expression levels in the
FIMM dataset (Supplementary Figure 2), suggesting that other
mechanisms regulate S100 expression.
The mRNA and Protein Expression
Profile of S100 Genes in MM Samples
To better understand S100 expression in MM, we analyzed
RNA sequencing data for the expression of the S100 family
members in 116 CD138+ cell samples from 95 different MM
patients (Supplementary Table 4). Based on mRNA abundance
in all samples, the most highly expressed S100 genes were
S100A4, S100A6, S100A9, S100A8, and S100A12 with a median
log2 (RPKM) range of 6.85 (S100A6) to 3.67 (S100A12). The
least abundantly expressed S100 genes were S100A7A, S100A7,
S100A14, S100A3, S100G, S100B, S100A16, S100A2, and S100A5,
with a median log2 (RPKM) range of −3.76 (S100A2) to −10.06
(S1007A) (Figure 2A). We further verified that S100 expression
profiles are comparable between the CoMMpass dataset (n = 892)
and our FIMM dataset, with a correlation coefficient of 0.70
(Supplementary Figures 3A,B). In the FIMM dataset, S100 genes
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FIGURE 1 | Prevalence and prognostic significance of S100 copy number change. (A) Location of the 17 S100 genes on chromosome 1q21.3. (B) Hierarchical
clustering of S100 genes in CD138+ plasma cells from 168 MM patient samples, using Euclidean distance matrix and complete clustering method, based on CNV
score. (C) The increased copy number of S100 genes correlated with poor overall survival. (D) Kaplan-Meier curves for MM patients with or without S100 gain.
Because patients with S100 gain were also more likely to have 1q21 gain, four groups were used for OS analysis and included: neither 1q21 gain nor S100 gain
(Neither), 1q21 gain present but no S100 gain (only 1q21 gain), S100 gain present but no 1q21 gain (only S100 gain), and 1q21 gain and S100 gain present (Both).
CNV score > 0.5 indicated a gain event, while <–0.6 is a deletion event. CNV, copy number variation; FIMM, Institute for Molecular Medicine Finland; OS, overall
survival; HR, hazard ratio; CI, confidence interval.
clustered into three subgroups based on expression, with group I
displaying the highest, group II intermediate, and group III the
lowest level of expression (Figure 2B).
The levels of S100 protein were determined by mass
spectrometry-based proteomics analysis of CD138+ cell
samples from 35 MM patients (Supplementary Table 5). Eight
S100 proteins (S100A4, S100A6, S100A8, S100A9, S100A10,
S100A11, S100A12, and S100P) were identified (Supplementary
Figure S3C). With the exception of S100P, all detected S100
proteins showed good correlation with gene expression level
(Supplementary Figure S3D).
Association of S100 Gene Expression
With Disease Status and Patient
Prognosis
Next, we investigated potential associations between S100 gene
expression and clinical features (disease status, ISS stage, patient
Frontiers in Cell and Developmental Biology | www.frontiersin.org 5 August 2021 | Volume 9 | Article 723016
fcell-09-723016 August 10, 2021 Time: 12:24 # 6
Liu et al. S100 Expression and PI Resistance
TABLE 1 | Correlation of S100 gain with disease stage and 1q21 gain in 168 MM
patient samples.
Variable S100 gain Without S100 gain P
No. % No. %
Disease stage 0.0001
NDMM 4 9.8 52 40.9
RRMM 37 90.2 75 59.1
1q21 gain <0.0001
Positive 35 85.4 43 33.9
Negative 6 14.6 84 66.1
RRMM, relapsed/refractory MM patients; NDMM, new diagnosed MM patients.
age, and gender), and with cytogenetic alterations in addition to
1q21+ in 116 MM patient samples (Supplementary Figure 4).
S100 genes with an overall expression of <1 RPKM were
not included in the analysis. S100A4 and S100A13 were more
highly expressed in RRMM versus NDMM patient samples.
S100A6 and S100A11 were more highly expressed in ISS
stage 3 compared with ISS stage 2. Elevated expression of
S100 genes were observed to associate with certain cytogenetic
makers, including S100A6 and S100A13 with 1q21 gain, S100A10
with del13q, S100A4, and S100A6 with t (4:14). In 54 paired
samples from the CoMMpass dataset, S100A4, S00A8, S100A9,
and S100A12 showed significant expression in first relapse
samples compared with the corresponding diagnostic samples
(Supplementary Figure 5).
To determine the effects of S100 gene expression on patient
survival we performed Kaplan-Meier analysis. In the FIMM
dataset, MM patients exhibiting high expression of S100A4
and S100A6 were more likely to have a poor prognosis
(Figure 3A). The median overall survival for high vs. low
expression samples was 73 vs. 100 months for S100A4 [hazard
ratio (HR) 1.71, 95% confidence limit (CL) 1.05–2.81; p < 0.05],
and 68 vs. 96 months for S100A6 (HR 1.90, 95% CL 1.17–
3.09; p < 0.01). In a multivariate analysis of variables associated
with OS, high S100A4 expression retained its significance
after adjusting for multiple covariates, including age, gender,
cytogenetic abnormality and other S100 genes (Table 2). The
association of high S100A4 expression with poor prognosis was
validated with the CoMMpass dataset (Figure 3B). In addition,
high expression of S100A10 was linked to poor survival in the
CoMMpass dataset (Figure 3B), but this was not observed in the
smaller FIMM cohort.
Correlation of S100 Expression With
Drug Sensitivity in MM Patient Samples
To assess the impact of S100 gene expression on drug response,
we correlated gene expression with ex vivo drug sensitivity data
for 308 drugs in 106 MM patient samples. Surprisingly, we
found that higher expression of S100A8, S100A9, and S100A12
inversely correlated with sensitivity to two approved MM drugs,
the PI bortezomib and HDAC inhibitor panobinostat, with a
Spearman’s correlation coefficient around 0.5 and false discovery
rate (FDR) < 0.05 (Figures 4A,B and Supplementary Table 6).
Expression of these S100 genes significantly negatively correlated
with the sensitivity to other approved PIs including carfilzomib
and ixazomib (Supplementary Table 6). The inverse correlation
between S100 gene expression and drug sensitivity extended to
other inhibitors including those targeting PI3K, IGF1R, PKC and
PI3K/mTOR (Supplementary Table 6). However, considering
drugs approved for MM, we focused on PIs and panobinostat for
further study. A comparison of proteomic and drug sensitivity
data from 35 MM patients also showed that the level of S100A8
and S100A9 proteins negatively correlated with bortezomib
and panobinostat sensitivity (Figure 4C and Supplementary
Table 7). Moreover, when accounting for 100 genes located on
chromosome 1q21, the associations of the genes in this region
with PI sensitivity were analyzed. The data showed S100 members
were on the top list of PI-correlated genes, in comparison to other
genes with 1q21 region (Supplementary Table 8), highlighting
the important role of S100 genes in PI response.
Using a set of two samples taken from the same patient at
diagnosis and at relapse when the patient had become resistant
to bortezomib-based treatment, we analyzed for changes in the
level of S100A8, S100A9, and S100A12 expression. In accordance
with the clinical response, our ex vivo analysis showed exceptional
sensitivity to bortezomib in pre-treatment sample (2700_2), but
resistant in the sample taken at relapse (2700_5) (Figure 4D).
Furthermore, S100A8, S100A9, and S100A12 were more highly
expressed in the bortezomib resistant sample than in the pre-
treatment sample (Figure 4D).
Clinical Relevance of S100A4
Overexpression for Carfilzomib
Resistance
Analysis of proteomic data revealed that high expression of
S100A4 protein significantly correlated to ex vivo resistance to
carfilzomib in 35 MM patients (Figure 5A). To validate this
finding, we collected S100A4 expression data of several MM cell
lines from the Keats Lab7, and performed drug sensitivity testing
of the same cell lines with different PIs. The analysis showed
response to carfilzomib was much better in S100A4 low cell lines
(SK-MM-1, OPM-2, and MM.1S) vs. S100A4 high expressing cell
lines (KMS-12-BM, NCI-H929, and U-266) (Figures 5B,C). In
addition, combining proteomic data from the DepMap portal8
and our drug sensitivity data, we found that the cell lines KMS-
12-BM and NCI-H929 which have high levels of S100A4 protein
were more resistant to carfilzomib compared to the OPM-2
cell line which had lower levels of S100 protein expression
(Figure 5B). Furthermore, to explore the clinical relevance of this
finding, we assessed for association of S100A4 gene expression
and survival of MM patients (n = 63) who received first line
carfilzomib-based therapy in the CoMMpass dataset. Survival
analysis revealed high expression of S100A4 and S100A10 linked
to shorter progression free survival (PFS), with median PFS:
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FIGURE 2 | Expression profile of S100 family genes in multiple myeloma samples. (A) Boxplot showing the log2 (RPKM) expression of S100 and housekeeping
genes from 116 MM samples. Genes are ranked based on median expression values. (B) Hierarchical clustering of S100 genes and patient samples using Euclidean
distance matrix and complete clustering method.
DISCUSSION
Chromosome 1q21 gain, a common genetic abnormality in
MM, is associated with poor prognosis in MM (An et al.,
2014). Although some genes within this region have been shown
to impact MM disease progression (Shaughnessy, 2005), the
molecular mechanisms resulting in 1q21 gain and whether it is
a cause or a consequence of the disease remain elusive. Seventeen
S100 genes are in the chromosome 1q21 region, all of which could
potentially contribute to cancer progression (Bresnick et al.,
2015). In this study, we systematically studied the roles of S100
family members in MM at the copy number, transcriptional and
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FIGURE 3 | Association of S100 gene expression with patient prognosis. (A) High expression of S100A4 and S100A6 associate with poor prognosis in the FIMM
dataset consisting of 116 MM samples. Low and high are defined as expression below and above the median value. (B) Higher expression of S100A4 and S100A10
are associated with shorter OS and PFS in the CoMMpass dataset including 800 MM samples. Patients were divided into groups with expression levels above the
75% percentile (high expression) and below 25% percentile (low expression). OS, overall survival; PFS, progression free survival; HR, hazard ratio; CI, confidence
interval; FIMM, Institute for Molecular Medicine Finland.
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TABLE 2 | Multivariate analysis of overall survival in the FIMM dataset (n = 116).
Variable HR* 95% CI* P
Age, years 0.94 0.90–0.98 0.002
Male 1.53 0.79–2.96 NS
Cytogenetic
t(11,14) 0.34 0.13–0.90 <0.05
t(4,14) 1.21 0.61–2.38 NS
del(17p) 1.24 0.59–2.60 NS
del(13q)/−13 1.0 0.56–1.78 NS
1q gain 0.93 0.47–1.84 NS
S100 gene
S100A4 1.40 1.10–1.77 0.006
S100A8 0.85 0.56–1.30 NS
S100A6 0.97 0.72–1.31 NS
S100A9 0.98 0.65–1.48 NS
S100A10 0.92 0.75–1.12 NS
S100A11 1.12 0.86–1.47 NS
S100A12 1.09 0.78–1.51 NS
S100A13 1.06 0.79–1.42 NS
*HR and 95% CIs were derived from a multivariable Cox proportional hazards
regression model. All the variables in the table were included in the same
model simultaneously.
protein levels using data collected from individual patients as well
as paired data from the same patients.
We studied a cohort of 168 MM patient samples and
found that 24% displayed copy number gains of S100
genes, including S100A1, S100A2, S100A3, S100A4, S100A5,
S100A6, S100A7, S100A7A, S100A8, S100A9, S100A10, S100A11,
S100A12, S100A13, S100A14, S100A16, and TCHLL. Survival
analysis also revealed the gains of these S100 genes associated
with poor patient prognosis in our FIMM dataset and the
MMRF CoMMpass dataset. It is widely accepted that copy
number abnormalities confer a selective advantage for tumor
development and metastasis (Weaver and Cleveland, 2007; Bolli
et al., 2018). Our results indicated prognostic roles of S100
copy number changes in MM patients. However, for most
S100 genes, copy number changes did not significantly correlate
with mRNA expression. The mRNA expression profiles showed
high expression of S100A4, S100A6, S100A8, S100A9, and
S100A12, and low expression of S100A7A, S100A7, S100A14,
S100A3, S100A16, S100A2, and S100A5, although all are in
the 1q21 region and had similar copy number gains in 116
MM patient samples. Numerous regulatory mechanisms can
control and disrupt mRNA transcription, such as transcription
factors, microRNAs and epigenetic modifiers, besides CNV. For
example, DNA hypomethylation resulted in reduced S100A6
and S100A10 expression in medulloblastoma while somatic
methylation controlled S100A2 and S100A4 expression in the
normal cerebellum, showing tissue specific regulation (Lindsey
et al., 2007). Diminished S100A2 expression was shown to
correlate with increased methylation in small cell lung cancer
cells and metastatic head and neck cancer (Leśniak, 2011).
Downregulation of miR-520c induced S100A4 expression in
colorectal cancer (Giridhar et al., 2017). Furthermore, S100
expression can be induced by certain growth factors, cytokines,
toll-like receptor (TLR) ligands, and intracellular signaling
cascades. For example, the pro-inflammatory cytokine IL-10 can
upregulate S100A8 expression (Endoh et al., 2009) and integrin
signals via Src kinase lead to increased S100A4 expression
(Kim et al., 2009). We observed high correlation between
mRNA and protein expression levels, suggesting that mRNA
expression levels of S100 genes are reflective of protein level
expression in MM.
In the second part of this study, we explored the clinical
relevance of S100 expression in MM. S100A4 and S100A13
were significantly more highly expressed in RRMM vs. NDMM
patients. In serial samples from the CoMMpass data, S100A4
also showed significant expression in first relapse samples vs.
the corresponding diagnostic samples. Survival analysis showed
elevated expression of S100A4 could predict poor survival of
MM patients in our FIMM dataset and the MMRF CoMMpass
dataset. S100A4 remained an independent predictor of inferior
survival after adjusting for multiple variables, including the
high-risk cytogenetic abnormalities. S100A4 (also known as a
metastasin-1), a metastasis -associated protein and an epithelial
to mesenchymal transition (EMT) marker, promotes cell survival
and proliferation, angiogenesis, invasion and metastasis, and
tumor-promoting inflammation and has been implicated in
cancer progression and metastasis (Helfman et al., 2005; Sherbet,
2009). S100A4 has been reported to be expressed in the nucleus,
cytoplasm, and extracellular space of many cells. Once secreted by
the cell, extracellular S100A4 can activate NF-κB and participate
in paracrine and/or autocrine signaling through binding to their
receptor TLR4 and RAGE as well as other cell surface receptors
(Donato et al., 2013). It is possible the effects of S100A4 on
MM progression and patient survival by its extracellular and
intercellular functions. S100A13 acts as an angiogenic marker for
melanoma (Massi et al., 2010; Azimi et al., 2014) and has been
involved in invasiveness of lung cancer cell lines (Miao et al.,
2018). The functions of S100A13 in MM remain unclear and need
further investigations.
Lastly, we integrated S100 gene expression and ex vivo drug
sensitivity data, including 308 approved and investigational
drugs, to determine whether the expression of S100 genes
correlate with drug response, especially established myeloma
drugs. The associations of S100 gene expression with our ex vivo
drug sensitivity data revealed S100A8, S100A9, and S100A12
expression inversely correlated with bortezomib, carfilzomib
and panobinostat sensitivity, all of which have been approved
for the treatment of MM. Analysis of S100 protein levels
confirmed a similar pattern with mRNA levels. In a paired
set of diagnosis-relapse samples from the same patient, these
genes were more highly expressed after the patient became
resistant to bortezomib-based treatment. In line with our
findings, a previous study showed inhibition of S100A9 results
in decreased viability and proliferation of MM cells and
overcomes resistance to bortezomib (De Veirman et al., 2017).
S100A8 and S100A9 exist as homodimers and heterodimers.
S100A8/S100A9 (also called calprotectin) has both intercellular
and extracellular functions. Upregulation of S100A8 and S100A9
occurs in various human cancer types and may participate in
tumor growth, metastasis, angiogenesis and immune evasion
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FIGURE 4 | Correlation of S100 expression with ex vivo drug response of MM patient samples. (A) Representation of correlating drug sensitivity with S100 gene
expression. Dot size indicates the number of tested MM patient samples, whereas dot color indicates approval status of the drugs. (B) High expression of S100A8,
S100A9, and S100A12 has a negative correlation with bortezomib sensitivity. (C) p-value distribution of S100 protein associated with the sensitivity to bortezomib
and panobinostat. (D) Bortezomib sensitivity and expression of S100A8, S100A9, and S100A12 in serial samples from patient 2700, who had complete remission in
first line (2700_2) and no response at relapse (2700_5) with bortezomib-dexamethasone-lenalidomide treatment.
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FIGURE 5 | S100A4 overexpression linked to carfilzomib resistance. (A) Correlation of S100 protein expression with ex vivo carfilzomib sensitivity. (B) CFZ score in
the MM cell lines having high and low–level expression of S100A4. Gene and protein expression presented as log2 FPKM value and log2 LFQ intensity, respectively.
(C) Statically analysis of CFZ DSS value in the MM cell lines expressing high vs. low expression. (D) High expression of S100A4 and S100A10 correlated with shorter
progression free survival in 63 MM patients, who received first-line carfilzomib-based therapy from the CoMMpass dataset. Low and high are defined as expression
below and above the median value. CFZ, carfilzomib; DSS, drug sensitivity score; PFS, progression free survival.
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(Ichikawa et al., 2011; Grebhardt et al., 2014; Goh et al., 2017;
Mondet et al., 2021). Elevated expression of S100A8/S100A9
caused glucocorticoid resistance in MLL rearranged infant
acute lymphoid leukemia (Spijkers-Hagelstein et al., 2012)
and negatively associated with BCL2 inhibitor venetoclax in
AML (Karjalainen et al., 2019). Our data suggest S100A8
and S100A9 expression may predict PI response and targeting
S100A8 or S100A9 may have therapeutic value. In addition,
a negative association between S100A4 protein expression and
carfilzomib sensitivity was observed in our dataset and in
MM cell lines we found that higher S100A4 expression also
linked to carfilzomib resistance. From the CoMMpass dataset
higher S100A4 gene expression significantly correlated with
lower PFS for MM patients who received carfilzomib-based
therapy, suggesting S100A4 maybe a therapeutic target for MM
patients. We acknowledge, however, that this finding requires
further exploration. Previous studies showed knockdown of the
S100A4 gene could alter cell metabolism and promote invasion
of lung cancer (Liu et al., 2019), restrict metastasis formation in
colorectal cancer (Dahlmann et al., 2012), reduce the proliferative
and invasive capacities of highly invasive prostate cancer cells
(Saleem et al., 2006), and resulted in cell death in leukemia
cells (Alanazi et al., 2020). Overexpression of S100A4 conferred
human cancer cell lines resistant to the chemotherapeutic drug
methotrexate (Mencía et al., 2010) and suppression of the
S100A4 gene increased sensitivity of pancreatic cancer cells to
gemcitabine treatment (Mahon et al., 2007). In a recent study,
S100A4 showed significant upregulation in MM non-responding
vs. responding patients treated with KARA-KRD (Cohen et al.,
2021). These studies indicate the potential role of S100A4 gene
in MM progression and drug response, and suppression of
S100A4 gene may contribute to a novel therapeutic approach
for MM treatment.
Our study has limitations. Notably, most patients received a PI
combined with other therapeutic agents, making it is difficult to
make a direct connection between S100 expression and clinical PI
response. However, our drug sensitivity assays testing individual
PIs with primary MM patient cells and with MM cell lines showed
a clear association between S100 expression and PI sensitivity.
Nevertheless, gain- and loss- of function experiments are needed
to study whether the S100 genes are a causal factor in MM
progression or PI and panobinostat resistance.
CONCLUSION
In conclusion, gains of S100 genes at 1q21 are frequent in MM
and associate with poor prognosis. High expression of S100
members in MM such as S100A4, S100A6, S100A8, S100A9, and
S100A12, indicate a possible role in disease development, while
higher expression S100A4 and S100A13 in RRMM vs. NDMM
suggest a role in disease progression. Furthermore, higher
expression of S100A4, S100A8, S100A9, and S100A12 correlated
with reduced ex vivo sensitivity to PIs and panobinostat. The
results were corroborated clinically where higher expression of
S100A4 was significantly linked to shorter PFS in patients given
carfilzomib-based therapy. Overall, these data indicate that S100
family members have predictive value in MM, may potentially
adapt MM cells to PI-based treatment, and could be potential
therapeutic targets.
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